Correlation of PET standard uptake value and CT window-level thresholds for target delineation in CT-based radiation treatment planning

International Journal of Radiation Oncology Biology Physics

Volumn 67, Issue 3, 2007, Pages 720-726

  Hong, Robert ^a   Halama, James ^a   Bova, Davide ^a   Sethi, Anil ^a   Emami, Bahman ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

NSCLC; Positron emission tomography (PET); Radiotherapy; Standard uptake value (SUV); Target delineation

Indexed keywords

CALIBRATION; CELLS; COMPUTER SOFTWARE; COMPUTERIZED TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; TUMORS;

GROSS TUMOR VOLUMES (GTV); RADIATION TREATMENT PLANNING; STANDARD UPTAKE VALUE (SUV); TARGET DELINEATION;

RADIOTHERAPY;

FLUORODEOXYGLUCOSE F 18;

ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG UPTAKE; HUMAN; LUNG NON SMALL CELL CANCER; OBSERVER VARIATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STANDARD; TREATMENT PLANNING; TUMOR VOLUME;

CARCINOMA, NON-SMALL-CELL LUNG; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; OBSERVER VARIATION; PHANTOMS, IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33846821671     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.09.039     Document Type: Article

References (31)

1. Dillman R.O., Herndon J., Seagren S.L., et al. Improved survival in stage III NSCLC: Seven year follow-up of CALGB 8433 trial. J Natl Cancer Inst 88 (1996) 1210-1215
2. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 17 (1999) 2692-2699
3. Lau D.H., Crowley J.J., et al. Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide and radiation for poor-risk stage III non-small cell lung cancer. J Clin Oncol 16 (1998) 3078-3081
4. Sawyer T.E., and Bonner J.A. Unresectable or medically inoperable NSCLC: The use of established clinical prognostic factors in making radiation-related treatment decisions. Semin Radiat Oncol 10 (2000) 267-273
5. Armstrong J., Raben A., Zelefsky M., et al. Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. Radiother Oncol 44 (1997) 17-22
6. Rengan R., Rosenzweig K.E., Venkatraman E., et al. Improved local control with higher doses of radiation in large-volume Stage III NSCLC. Int J Radiat Oncol Biol Phys 60 (2004) 741-747
7. Narayan S., Henning G.T., Ten Haken R.K., et al. Results following treatment to doses of 92.4 or 102.9 Gy on a phase I dose escalation study for non-small cell lung cancer. Lung Cancer 44 (2004) 79-88
8. Sanjiv S., Gambhir, Czernin J., et al. A tabulated summary of the FDG PET literature. J Nucl Med 42 (2001) 1-93
9. Sasaki M., Ichiya Y., Kuwabara Y., et al. The usefulness of FDG PET for the detection of mediastinal lymph node metastases in patients with NSCLC: A comparative study with X-ray computed tomography. Eur J Nucl Med 23 (1996) 741-747
10. Bayne M., Everitt S., MacManus M., et al. Fused PET/CT images for planning radical radiotherapy for NSCLC. Lung Cancer 49 Suppl. 3 (2005) S74-S75
11. MacManus M.P., Hicks R., Matthews J., et al. Long-term follow-up of 153 candidates for definitive radiation or chemoradiation therapy with non-small cell lung cancer who were staged by PET: Implications for design of future randomized trials. Int J Radiat Oncol Biol Phys 63 Suppl. 1 (2005) S223-S224
12. Bradley J., Thorstad W., Mutic S., et al. Impact of FDG-PET on radiation therapy volume delineation in NSCLC. Int J Radiat Oncol Biol Phys 59 (2004) 78-86
13. Mah K., Caldwell C., Ung Y., et al. The impact of FDG-PET on target and critical organs in CT based treatment planning of patients with poorly defined NSCLC: A prospective study. Int J Radiat Oncol Biol Phys 52 (2002) 339-350
14. Giraud P., Grahek D., Montravers F., et al. CT and FDG image fusion for optimization of conformal radiotherapy of lung cancers. Int J Radiat Oncol Biol Phys 49 (2001) 1249-1257
15. Steenbakkers R., Duppen J., Fitton I., et al. Reduction of observer variation using matched CT-PET for lung cancer delineation: A three-dimensional analysis. Int J Radiat Oncol Biol Phys 64 (2006) 435-448
16. Huang S.C. Anatomy of SUV. Standardized uptake value. Nucl Med Biol 27 (2000) 643-646
17. Vansteenkiste J.F., Stroobants S.G., Dupont P.J., et al. Prognostic importance of the standardized uptake value on FDG PET in NSCLC: An analysis of 125 cases. J Clin Oncol 17 (1999) 3201-3206
18. Erdi Y., Rosenzweig K., Erdi A., et al. Radiotherapy treatment planning for patients with NSCLC using PET. Radiother Oncol 62 (2002) 51-60
19. Erdi Y.E., Mawlawi O., Larson S.M., et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer 80 12 Suppl. (1997) 2505-2509
20. Black Q.C., Grills I.S., Kestin L.L., et al. Defining a radiotherapy target with positron emission tomography. Int J Radiat Oncol Biol Phys 60 (2004) 1272-1282
21. Caldwell C.B., Mah K., Ung Y.C., et al. Observer variation in contouring gross tumour volume in patients with poorly defined NSCLC on CT: The impact of FDG PET fusion. Int J Radiat Oncol Biol Phys 51 (2001) 923-931
22. Van de Steene J., Linthout N., de Mey J., et al. Definition of gross tumor volume in lung cancer: Inter-observer variability. Radiother Oncol 62 (2002) 37-49
23. Giraud P., Elles S., Helfre S., et al. Conformal radiotherapy for lung cancer: Different delineation of the gross tumor volume (GTV) by radiologists and radiation oncologists. Radiother Oncol 62 (2002) 27-36
24. MacManus M.P., Hicks R.J., Matthews J.P., et al. Positron emission tomography is superior to computed tomography scanning for response assessment after radical radiotherapy or chemoradiotherapy in patients with non-small cell lung cancer. J Clin Oncol 21 (2003) 1285-1292
25. Lardinois D., Weder W., Hany T.F., et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348 (2003) 2500-2507
26. MacManus M.P., Hicks R.J., Ball D.L., et al. F-18 fluorodeoxy-glucose positron emission tomography staging in radical radiotherapy candidates with non small cell lung carcinoma: Powerful correlation with survival and high impact on treatment. Cancer 92 (2001) 886-895
27. Vansteenkiste J.F., Stroobants S.G., DeLyn P.R., et al., The Leuven Lung Cancer Group. Potential use of FDG-PET scan after induction chemotherapy in surgically staged NSCLC: A prospective pilot study. Ann Oncol 9 (1998) 1193-1198
28. Vansteenkiste J.F., Stroobants S., Hoekstra C., et al. 18fluoro-2-deoxyglucose positron emission tomography (PET) in the assessment of induction chemotherapy (IC) in stage IIIA-N2 NSCLC: A multi-center prospective study. Proc Am Soc Clin Oncol 20 (2001) 313A
29. Nestle U., Walter K., Schmidt S., et al. FDG-PET for the planning of radiotherapy in lung cancer: High impact in patients with atelectasis. Int J Radiat Oncol Biol Phys 44 (1999) 593-597
30. Vanuytsel L.J., Vansteenkiste J.F., Stroobants S.G., et al. The impact of FDG-PET lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol 55 (2000) 317-324
31. Paulino A.C., and Johnstone P. FDG-PET in radiotherapy treatment planning: Pandora's box?. Int J Radiat Oncol Biol Phys 59 (2004) 4-5